Newsletters

[Signal Transduction and Targeted Therapy] Researchers identified Zinc finger MIZ domain-containing protein 1 (ZMIZ1) as a previously unrecognized transcriptional co-regulator that enforces differentiation blockade in AML from a targeted CRISPR-Cas9 screen.

[Nature Cell Biology] By performing single-cell transplantations of over 1,000 highly purified murine long-term HSCs combined with in-depth phenotyping of their clonal progeny, scientists defined kinetics-based reconstitution parameters which aligned HSCs into a single hierarchical trajectory reflective of functional potency.

[Blood] To understand the connection between chromatin accessibility and GATA1, investigators comprehensively studied erythropoiesis in Stag2∆ mice.

[Nature Cancer] Scientists used a targeted in vivo CRISPR screen to identify nutritional dependencies of systemic and central nervous system acute lymphoblastic leukemia.

[Nucleic Acids Research] The authors identified a conserved set of seven zinc finger protein (ZNF) genes, including ZNF184, that are upregulated in acute lymphoblastic leukemia and exhibit dynamic expression patterns linked to disease progression.

[Nature Communications] Researchers showed that clonal hematopoiesis (CH) co-occurrences are selected for in the aging population and identified CH clones with notable implications for future malignancy risk.

[Clinical Chemistry and Laboratory Medicine] Investigators validated the utility of flow cytometric detection of nPAX5 for the diagnosis of B-lymphoblastic leukemia, potentially enhancing diagnostic efficiency.

[Blood Advances] Scientists reported the outcomes of a multicenter, open-label Phase Ib study of ABBV-744 in patients with myelofibrosis who received ≥1 previous lines of therapy, including a Janus kinase inhibitors.

[Blood Advances] In a Phase II trial, participants with essential thrombocythemia who required cytoreduction and had inadequate response to, or were intolerant of, ≥1 standard therapy received bomedemstat at a starting dose of 0.6 mg/kg per day, titrated to achieve a target platelet count

[Current Treatment Options in Oncology] The authors propose CRISPR-enhanced CARs and synthetic biology-based allogeneic systems to enhance the efficacy and accessibility of CAR-T therapy with the aim of moving the field of oncology towards durable cures.

[Taiho Oncology, Inc. (Business Wire)] Taiho Oncology, Inc. announced that the US FDA has approved INQOVI plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia who are 75 years or older or who are ineligible for intensive induction chemotherapy.

[CellChorus, Inc.] CellChorus, Inc. announced that the National Cancer Institute has awarded CellChorus® and Stanford Medicine a Phase I Small Business Innovation Research grant to profile cells from relapsed/refractory large B cell lymphoma patients after treatment with CAR-T cell therapy to develop a functional signature of response to therapy.